TW239131B - - Google Patents

Info

Publication number
TW239131B
TW239131B TW082106302A TW82106302A TW239131B TW 239131 B TW239131 B TW 239131B TW 082106302 A TW082106302 A TW 082106302A TW 82106302 A TW82106302 A TW 82106302A TW 239131 B TW239131 B TW 239131B
Authority
TW
Taiwan
Application number
TW082106302A
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Application granted granted Critical
Publication of TW239131B publication Critical patent/TW239131B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW082106302A 1992-08-06 1993-08-06 TW239131B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/926,795 US5310929A (en) 1992-08-06 1992-08-06 Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists

Publications (1)

Publication Number Publication Date
TW239131B true TW239131B (zh) 1995-01-21

Family

ID=25453732

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082106302A TW239131B (zh) 1992-08-06 1993-08-06

Country Status (18)

Country Link
US (1) US5310929A (zh)
EP (1) EP0654027A1 (zh)
JP (1) JP2892838B2 (zh)
CN (1) CN1090275A (zh)
AU (1) AU688735B2 (zh)
BR (1) BR9306911A (zh)
CA (1) CA2141692C (zh)
FI (1) FI950485A (zh)
HU (1) HU9500349D0 (zh)
IL (1) IL106553A0 (zh)
MX (1) MX9304787A (zh)
NO (1) NO950404D0 (zh)
PL (1) PL307309A1 (zh)
SG (1) SG47108A1 (zh)
SK (1) SK13195A3 (zh)
TW (1) TW239131B (zh)
WO (1) WO1994003435A1 (zh)
ZA (1) ZA935693B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
JP3501484B2 (ja) * 1992-12-17 2004-03-02 三共株式会社 ビフェニル誘導体
WO1995024902A1 (fr) * 1994-03-16 1995-09-21 Sankyo Company, Limited Reducteur de tension oculaire
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5510495A (en) * 1994-09-19 1996-04-23 The Du Pont Merck Pharmaceutical Company Process for the isolation and purification of ester functionalized imidazole intermediates by selective hydrolysis
EP0782996B1 (en) * 1994-09-20 1999-02-17 Wakunaga Seiyaku Kabushiki Kaisha Process for producing n-biphenylmethylthiadiazoline derivative or salt thereof and intermediate for producing the same
IT1292437B1 (it) * 1997-06-30 1999-02-08 Zambon Spa Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti
IT1295405B1 (it) * 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
ES2154191B1 (es) * 1998-11-24 2001-10-16 Ferrer Int Nuevos acetales derivados de los 2-alquil-5-halo-3-(2'-(tetrazol-5-il)-bifenil-4-ilmetil)-3h-imidazol-4-carbaldehidos.
GR20000100281A (el) * 2000-08-17 2002-05-24 Ιωαννης Ματσουκας Ανταγωνιστες του υποδοχεα της αγγεοτενσινης ιι και συνθετικες μεθοδοι για την θεραπεια της υπερτασης και καρδιοαγγειακων ασθενειων
WO2002096883A1 (en) 2001-05-31 2002-12-05 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists
EP1509517B1 (en) 2003-01-16 2008-06-11 Teva Pharmaceutical Industries Ltd. Novel synthesis of irbesartan
WO2005068632A1 (ja) 2004-01-20 2005-07-28 Aichi Prefecture ＨＬＡ−Ａ２４０２拘束性Ｅｐ−ＣＡＭ特異的ＣＴＬが認識するエピトープ・ペプチド及びその用途
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US20070054948A1 (en) * 2004-09-02 2007-03-08 Lilach Hedvati Purification of olmesartan medoxomil
WO2006029057A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Purification of olmesartan medoxomil
CA2604190A1 (en) * 2005-04-20 2006-11-02 Merck & Co., Inc. Angiotensin ii receptor antagonists
JP2009515834A (ja) * 2006-08-29 2009-04-16 テバ ファーマシューティカル インダストリーズ リミティド ５−フェニル−１−トリチル−１ｈ−テトラゾールの合成のための方法
AU2007306171B2 (en) * 2006-10-09 2013-02-21 Cipla Limited Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil
WO2008067687A1 (fr) * 2006-12-06 2008-06-12 Shanghai Allist Pharmaceutical., Inc. Sels de dérivés d'acide imidazol-5-carboxylique, procédés de préparation et utilisation
EP2521545B1 (en) * 2010-01-07 2019-11-27 Alkermes Pharma Ireland Limited Prodrugs of heteroaromatic compounds
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
CN104610232B (zh) * 2013-11-01 2019-09-20 深圳信立泰药业股份有限公司 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物
EP4007592A1 (en) 2019-08-02 2022-06-08 LanthioPep B.V. Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
WO1991000281A2 (en) * 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Fused-ring aryl substituted imidazoles
DE69025473T2 (de) * 1989-06-30 1996-10-17 Du Pont Substituierte imidazole und ihre verwendung als hemmmstoff fur angiotensin ii
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5137902A (en) * 1990-07-13 1992-08-11 E. I. Du Pont De Nemours And Company 4-alkylimidazole derivatives and anti-hypertensive use thereof
DK0573218T3 (da) * 1992-06-02 2001-06-18 Sankyo Co 4-carboxyimidazolderivater som angiotensin-II antagonister og deres terapeutiske anvendelse

Also Published As

Publication number Publication date
HU9500349D0 (en) 1995-03-28
JPH08500103A (ja) 1996-01-09
ZA935693B (en) 1995-02-06
FI950485A0 (fi) 1995-02-03
CA2141692A1 (en) 1994-02-17
AU4790393A (en) 1994-03-03
WO1994003435A1 (en) 1994-02-17
FI950485A (fi) 1995-02-03
SK13195A3 (en) 1995-07-11
PL307309A1 (en) 1995-05-15
IL106553A0 (en) 1993-12-08
BR9306911A (pt) 1998-12-08
SG47108A1 (en) 1998-03-20
CN1090275A (zh) 1994-08-03
CA2141692C (en) 2006-05-30
US5310929A (en) 1994-05-10
MX9304787A (es) 1995-01-31
JP2892838B2 (ja) 1999-05-17
EP0654027A1 (en) 1995-05-24
NO950404D0 (no) 1995-02-03
AU688735B2 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
DK0613608T3 (zh)
DK0553875T3 (zh)
DK0630289T3 (zh)
DK109593A (zh)
DK0596750T3 (zh)
BR9207065A (zh)
DK0632741T3 (zh)
DK114493A (zh)
DK0625187T3 (zh)
DK0581129T3 (zh)
DK0574276T3 (zh)
DK0596569T3 (zh)
DK0597323T3 (zh)
DK0599441T3 (zh)
DK131792D0 (zh)
BR9202713C1 (zh)
DE9209779U1 (zh)
DK117092D0 (zh)
DK11192D0 (zh)
DK127492D0 (zh)
AU2098792A (zh)
BR9304980A (zh)
AU1842892A (zh)
AU1861992A (zh)
AU634140B1 (zh)